22 October 2024

iLoF secures strategic investment from Hamamatsu Ventures to expand its photonics platform

The strategic backing from Hamamatsu Ventures will support international expansion and technological development.

$1.5M

iLoF operates a digital health platform that uses artificial intelligence and photonics to accelerate personalised medicine. The firm focuses on transforming healthcare and improving early disease detection.

iLoF has secured a strategic investment from Hamamatsu Ventures to advance its digital health technology. The funding supports the deployment of the company photonics platform and aids expansion into international markets including the United States and Japan. The partnership also seeks to integrate cutting-edge sensors to refine precision diagnostics and patient stratification.

The backing follows a clinical research contract secured earlier in the year by the London-based firm for a global study. That project involves deploying the technology in the Bio-Hermes-002 trial alongside the Global Alzheimer Foundation to transform neurodegenerative disease diagnosis.

From the founder

"This collaboration marks the beginning of an exciting new chapter for us, especially as we expand into the Japanese and Asia markets. Hamamatsu’s support has also been invaluable in our recently established U.S. operation, where their network has been helping us establish critical connections to scale our business."

Luís Valente

CEO at iLoF

Investor perspective

"At Hamamatsu, we understand that personalized medicine represents the future of healthcare innovation. We’ve been impressed with iLoF and the potential of their technology to accelerate early screening, and through investment, we hope to further explore synergies to transform the discovery of treatments for complex diseases and reshape how we approach diagnosis and drug discovery. We’re eager to see the impact of this collaboration and hope to contribute positively to patients and healthcare worldwide."

Moto Suyama

CTO, Hamamatsu Ventures